A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

Sponsors and Collaborators
Agensys, Inc.

Contact
Agensys Clinical Research and Development
310-820-8029
Clinical@Agensys.com

Principal Investigator
Medical Director, Agensys, Inc.

ClinicalTrials.gov Identifier
NCT01672775

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters